| Re-purposing cancer therapeutics for breast cancer immunotherapy. | |
| | |
MedLine Citation:
|
PMID: 22454154 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
After decades of work to develop immune-based therapies for cancer, the first drugs designed specifically to engage the host anti-tumor immune response for therapeutic benefit were recently approved for clinical use. Sipuleucel-T, a vaccine for advanced prostate cancer, and ipilimumab, a monoclonal antibody that mitigates the negative impact of cytotoxic T lymphocyte antigen-4 signaling on tumor immunity, provide a modest clinical benefit in some patients. The arrival of these drugs in the clinic is a significant advance that we can capitalize on for even better clinical outcomes. The strategic and scientifically rational integration of vaccines and other direct immunomodulators with standard cancer therapeutics should lead to therapeutic synergy and high rates of tumor rejection. This review focuses on the use of cyclophosphamide, doxorubicin, and HER-2-specific monoclonal antibodies to dissect mechanisms of immune tolerance relevant to breast cancer patients and illustrates how appropriate preclinical models can powerfully inform clinical translation. The immune-modulating activity of targeted, pathway-specific, small molecule therapeutics is also discussed. Fully understanding how cancer drugs impact the immune system should lead to the ultimate personalized cancer medicine: effective combinatorial immunotherapy strategies that simultaneously target signaling pathways essential for tumor growth and progression, and systematically break multiple, distinct immune tolerance pathways to maximize tumor rejection and effect cure. |
| | |
Authors:
|
Leisha A Emens |
Related Documents
:
|
17458584 - Temporal patterns in lung cancer death rates in ireland. 16962174 - Incidence of eyelid cancers in taiwan: a 21-year review. 20593934 - Cancer incidences in rural delhi--2004-05. 10975544 - Epidemiology of lymphomas. 8775994 - Helicobacter pylori infection and gastric cancer: usefulness of screening high risk gro... 12893204 - Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review Date: 2012-03-28 |
Journal Detail:
|
Title: Cancer immunology, immunotherapy : CII Volume: 61 ISSN: 1432-0851 ISO Abbreviation: Cancer Immunol. Immunother. Publication Date: 2012 Aug |
Date Detail:
|
Created Date: 2012-07-23 Completed Date: 2012-10-01 Revised Date: 2013-04-18 |
Medline Journal Info:
|
Nlm Unique ID: 8605732 Medline TA: Cancer Immunol Immunother Country: Germany |
Other Details:
|
Languages: eng Pagination: 1299-305 Citation Subset: IM |
Affiliation:
|
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231-1000, USA. emensle@jhmi.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal / therapeutic use Antineoplastic Agents / therapeutic use* Breast Neoplasms / immunology*, therapy* Congresses as Topic Cyclophosphamide / therapeutic use Doxorubicin / therapeutic use Female Humans Immunotherapy / methods* Receptor, erbB-2 / antagonists & inhibitors |
| Grant Support | |
ID/Acronym/Agency:
|
P50 CA088843/CA/NCI NIH HHS; P50CA88843/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; EC 2.7.10.1/ERBB2 protein, human; EC 2.7.10.1/Receptor, erbB-2 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Developmental programming: prenatal and postnatal contribution of androgens and insulin in the repro...
Next Document: Moral Distress: A Comparative Analysis of Theoretical Understandings and Inter-Related Concepts.